Factor 8 Hemlibra denied as not FDA-approved for this use by Aetna?

Aetna's specific coverage criteria for factor 8 hemlibra are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Cites "Not FDA-Approved" for Hemlibra — and Why You Can Appeal

Hemlibra (emicizumab-kxwh) is FDA-approved for prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A. A "not FDA-approved" denial for Hemlibra is almost always an administrative error — either the drug code was entered incorrectly, the claim was processed under the wrong benefit category, or the plan's system has not been updated to reflect the current approval status. Before investing in a full appeal, first contact Aetna's provider relations line to confirm whether this is a coding or processing error that can be corrected on redetermination.

## Why This Denial Is Appealable

If the denial persists after a redetermination request, it must be challenged formally. An FDA-approved drug used in its labeled indication cannot be denied solely on not-approved grounds without a documented clinical or administrative basis. External reviewers will confirm FDA approval status from the official prescribing information and are required to apply objective standards.

## Federal Appeal Framework

• ERISA §503 (self-funded plans): Full-and-fair review; file internally within 180 days of the denial.
• ACA §2719 (fully-insured plans): Independent external review after internal exhaustion; typically within four months of the final internal denial.
• Expedited review: Available if standard timelines would seriously jeopardize health or function; typically 72-hour resolution.

## Concrete Appeal Steps and Timeline

1. Call Aetna provider relations and request a redetermination, citing FDA approval status. 2. If the denial is not corrected, file a formal internal appeal within the stated deadline. 3. Attach the FDA-approved prescribing information for Hemlibra as an exhibit. 4. State in the appeal that the drug is FDA-approved, the use is within the labeled indication, and the denial basis is factually incorrect. 5. Escalate to external review if the internal appeal is denied.

## Documentation to Gather

• FDA prescribing information: The current Hemlibra (emicizumab-kxwh) FDA-approved package insert, identifying the approved indication.
• Diagnosis confirmation: Specialist-confirmed hemophilia A diagnosis, with inhibitor status where relevant, confirming the use falls within the labeled indication.
• Claim documentation: The original prior-authorization request or claim, drug codes used, and the denial notice — to identify any coding discrepancy.
• Prescriber letter: A brief letter from the treating hematologist confirming the drug and indication are FDA-approved and that the denial basis is factually incorrect.

## Criteria-Mapping Structure

For this denial type, the criteria-mapping is straightforward: obtain Aetna's not-FDA-approved policy and the official FDA approval record. Place them side by side. Show that the drug code, indication, and patient population align with the FDA-approved label. This type of appeal is often the shortest to write and the fastest to win — the factual record speaks for itself.